At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Acuvue Oasys +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)
In Brief
A Phase 4 clinical trial evaluating Acuvue Oasys and Air Optix Night & Day Aqua for Lid Wiper Epitheliopathy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study examines the development of Lid Wiper Epitheliopathy (LWE) in individuals fit with contact lenses having difference coefficients of friction (CoF)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLid Wiper Epitheliopathy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedJul 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedJul 6, 2017
Enrollment StartJun 26, 2017
Primary CompletionApr 13, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.0 years ago
Interventions
Acuvue Oasysdevice
FDA approved contact lens, fit for daily wear
Air Optix Night & Day Aquadevice
FDA approved contact lens, fit for daily wear